Physician profile
Eric H Stocker
NPI 1891765624
$229,451.96
in general payments reported to CMS, 2019-2025
20 companies · $9,360 in 2025
The $9,360 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64K · 2020: $999 · 2021: $76K · 2022: $43K · 2023: $9,137 · 2024: $28K · 2025: $9,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Travel and Lodging: $7,928 · Food and Beverage: $3,900 · Consulting Fee: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,786.75 |
| Travel and Lodging | $7,928.03 |
| Food and Beverage | $3,900.18 |
| Consulting Fee | $1,800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $143,865.99 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $75,830.37 | 2021-2024 | Nexletol |
| Althera Pharmaceuticals LLC | $4,047.76 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $2,988.95 | 2021-2025 | |
| Boston Scientific Corporation | $1,356.73 | 2023-2024 | Watchman Access System, Watchman Flx |
| Regeneron Healthcare Solutions, INC. | $352.02 | 2022-2025 | Evkeeza, Praluent |
| Janssen Pharmaceuticals, INC | $323.87 | 2021-2024 | Xarelto |
| Amarin Pharma, INC. | $166.82 | 2020-2023 | |
| Abbvie INC. | $120.19 | 2019 | |
| Merck Sharp & Dohme LLC | $90.14 | 2021-2022 | |
| Pfizer INC. | $41.81 | 2023-2024 | |
| Lilly USA, LLC | $39.31 | 2022 | |
| Agepha Pharma Fz LLC | $36.78 | 2024 | Lodoco |
| Azurity Pharmaceuticals, INC. | $36.70 | 2023 | Edarbi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.66 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $35.20 | 2021-2023 | Farxiga |
| Ionis Pharmaceuticals, INC. | $29.48 | 2025 | Tryngolza |
| Cvrx, INC. | $28.20 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.39 | 2023 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Stocker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.